Klin Onkol 2002; 15(6): 226-229.
Summary: Mucosal toxicity is one of the most frequent adverse effect in oncology. The consequences of mucosal toxicíty are systemic and often have influence on the course of antitumor therapy. The results could be influenced by the method, selection of patients and their collaboration not at least. In our modification of the 51Cr EDT A test, we abandoned volumetric treatment, which was replaced by a more sensitive method. We investigated 59 patients with various oncological therapy. We did not detect any changes in intestinal permeability after the radiotherapy of patients with rectal carcinomas, nor in patients with spinocellular carcínomas or gynecological malignancies. Similarly, we could not detect significant differences in a group of We detected significant changes of intestinal permeability during the course of treatment of fluorouracil according to Mayo using the 51Cr EDTA test and conflrmed the well-known mucosal toxicity of fluorouracíl. We also found statistically significant changes in intestinal permeability in patients treated for advanced lymphomas using combined regirnens and cyclophospharnide. However, the numbers are too small for conclusive proof whether the general patienťs status or just chemotherapy is the main reason for detected changes in intestinal permeability. The advantages of the 51Cr EDT A test are excellent tolerance and acceptable costs. The disadvantage of the test is a 24-hour collection of urine and the use of a radioisotope.
